Nicotine e-cigarettes outperform patches and gum for quitting smoking

Researchers have found that nicotine e-cigarettes help more smokers quit than traditional nicotine replacement therapies like patches and gum. A review of 14 systematic studies from 2014 to 2023 shows consistent high-quality evidence favoring nicotine vapes. The findings highlight gaps in research on long-term risks and comparisons to other treatments.

A team led by Dr. Angela Difeng Wu from the University of Oxford's Nuffield Department of Primary Care Health Sciences analyzed 14 systematic reviews on smoking cessation methods. The highest-quality studies consistently demonstrated higher quit rates with nicotine e-cigarettes compared to nicotine patches, gum, lozenges, non-nicotine e-cigarettes, and behavioral support programs alone. Lower-quality research showed more mixed results, but the strongest evidence supports nicotine e-cigarettes as more effective. The work, published in the journal Addiction, was funded by Cancer Research UK. Dr. Wu stated, 'We hope this overview and Evidence and Gap Map can lay to rest some claims that evidence is mixed regarding the impacts of nicotine e-cigarettes on smoking abstinence. In fact, the evidence is clear and consistent across all of the meta-analyses we consulted: e-cigarettes are effective at helping people stop smoking.' Researchers created an Evidence and Gap Map to identify research needs. No high-quality reviews compare nicotine e-cigarettes to cytisine, bupropion, or nicotine pouches, and evidence against varenicline comes from just one small, high-bias study. Data on serious adverse events remains uncertain, and most studies focus on high-income countries. The authors call for more research on risks and diverse populations.

相关文章

Drug commissioner Hendrik Streeck at press conference urging ban on sweet-flavored e-cigarettes to safeguard youth from addiction.
AI 生成的图像

Drug commissioner Streeck calls for ban on sweet flavors in e-cigarettes

由 AI 报道 AI 生成的图像

The federal government's drug commissioner, Hendrik Streeck, advocates for banning sweet flavors in e-cigarettes to protect young people. He criticizes the marketing as an addiction strategy and welcomes planned bans on 13 ingredients. Addiction researcher Heino Stöver, however, considers the measures unjustified.

Law 2354 of 2024 aims to regulate nicotine electronic systems and similar products, but its implementation faces significant delays. Two years after promulgation, key provisions like mandatory labeling and advertising bans remain unenforced. This allows uncontrolled circulation of vapes among teens, per Ministry of Justice data.

由 AI 报道

国家烟草专卖局于周四发布电子烟行业草案政策,旨在减少该行业的过剩产能,并加强生产和出口标准的执行。该政策继本月早些时候国务院意见之后,进一步加强对电子烟和尼古丁袋的监管。

A new study from the University of Gothenburg shows that tirzepatide, the active ingredient in the diabetes and weight loss drug Mounjaro, reduces alcohol intake and relapse-like behaviors in rats and mice. This builds on prior research on semaglutide in Ozempic and Wegovy, which curbs alcohol consumption in humans. Researchers hope for similar effects in patients with alcohol dependence.

由 AI 报道

A new review of clinical trials suggests that psychedelics like psilocybin are effective for treating depression but offer no advantage over traditional antidepressants. Researchers accounted for the challenge of blinding in psychedelic studies, where participants can often tell if they received the drug. The findings indicate similar outcomes when compared to unblinded antidepressant trials.

British American Tobacco is shutting down its Heidelberg manufacturing plant in South Africa, leading to 230 job losses, as it shifts to importing cigarettes amid a booming illicit trade. At the same time, the company is continuing an aggressive share buyback program in London to reward shareholders. Workers and experts point to government inaction on illegal cigarettes as a key factor in the decline.

由 AI 报道

A comprehensive review of clinical trials suggests that cannabis products high in THC may provide modest, short-term relief for chronic pain, especially neuropathic types, but with notable side effects. In contrast, CBD-dominant products offer no clear advantages. Researchers call for more long-term studies to assess safety and efficacy.

 

 

 

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝